28
Falk Symposium 162 Liver Cirrhosis: From Pathophysiology to Disease Management October 13 – 14, 2007 International Congress Center Dresden Program Awarded with 9 CME credits
Falk Symposium 162
Liver Cirrhosis: From Pathophysiologyto Disease Management
October 13 – 14, 2007International Congress Center Dresden
Program Awardedwith
9CME credits
Preface . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
Scientific Program . . . . . . . . . . . . . . . . . . . . . . . . . 6
Posters . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
List of Speakers . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
City Map of Dresden . . . . . . . . . . . . . . . . . . . . . . . 27
9 credit hours (CME) have been awarded for the Falk Symposium 162by the European Union of Medical Specialists (UEMS) – European Board of Gastroenterology (EBG).
3
▼▼
▼▼
▼▼
Preface
Dear Colleagues and Friends,
Liver cirrhosis is a leading cause of morbidity and mortality worldwide. It is thefifth most common cause of death between the age of 25 and 45 years. Todate it is not possible to inhibit or revert progression of cirrhosis in mostpatients. Accordingly, clinicians have to deal primarily with the various compli-cations of cirrhosis, while liver transplantation is only available for selectedpatients.
There has been tremendous progress in understanding liver fibrosis and cir-rhosis since the last Falk Symposium devoted to this topic in 2000. This FalkSymposium 162 focuses on the pathogenetic mechanisms of liver cirrhosisand clinical management of the complications. In the first three sessions, wewill discuss liver fibrogenesis and the cellular responses to chronic liver injuryas well as new non-invasive techniques for assessment of fibrosis in patients.On the second day, we will focus on preprimary and primary prophylaxis ofvariceal bleeding and therapy of other complications of cirrhosis.
Following the tradition of the international Falk meetings, this Falk Sympo-sium 162 will feature plenary talks from key investigators and clinicians in thefield as well as poster presentations. Scientific and clinical experts will offer abroad understanding and pave the ground for interdisciplinary discussion.Thus, the meeting will provide a blueprint for research and clinical manage-ment of liver cirrhosis, the most prevalent sequelae of chronic liver diseasesworldwide.
We are looking forward to welcoming hepatologists, gastroenterologists aswell as clinical researchers and trainees to this exciting scientific meeting inDresden.
Jaime BoschAndrew K. BurroughsFrank LammertDidier LebrecTilman Sauerbruch
4
Falk Symposium 162
Liver Cirrhosis: From Pathophysiologyto Disease Management
International Congress Center Dresden
Registration:Friday, October 12, 20078.00 – 19.30 hat the congress office
Scientific Organization:J. Bosch, Barcelona (Spain)A. K. Burroughs, London (Great Britain)F. Lammert, Bonn (Germany)D. Lebrec, Clichy (France)T. Sauerbruch, Bonn (Germany)
Congress Venue:International Congress Center DresdenOstra-Ufer 201067 DresdenGermany
Information:Prof. Dr. Tilman SauerbruchMedizinische Klinik IUniversitätsklinikum BonnSigmund-Freud-Str. 2553127 BonnGermanyPhone: +49(0)228/28 71-52 55Fax: +49(0)228/28 71-43 22E-Mail: [email protected]
Official language:English and German(Simultaneous translation)
Posters:For details see page 10.
5
Saturday, October 13, 2007
8.50 Welcome introductory remarks T. Sauerbruch,Bonn
Session IPathomechanisms of fibrogenesis (1) : InitiationChair: S. L. Friedman, New York; D. Häussinger, Düsseldorf
9.00– Apoptosis and oncotic necrosis: The common pathways H.W. Jaeschke,9.15 of liver injury Kansas City
9.20– Entero-hepatic lymphocyte homing and liver manifestations D. Adams,9.35 of IBD Birmingham
9.40– Immune response to chronic hepatitis C virus infection U. Spengler,9.55 Bonn
10.00– Cytokines: Interleukin 6- and TNF-signalling C. Trautwein,10.15 Aachen
10.20 Coffee break with poster session
Session IIPathomechanisms of fibrogenesis (2): MediatorsChair: D. A. Brenner, La Jolla; A. M. Gressner, Aachen
10.40– Growth factors in experimental liver fibrogenesis R. Weiskirchen,10.55 Aachen
11.00– Genetic determinants of liver fibrogenesis F. Lammert,11.15 Bonn
11.20– Molecular mechanims of fibrosis progression in NASH C. Hellerbrand,11.35 Regensburg
11.40– New role of bile acid metabolism in bacterial A. Moschetta,11.55 translocation Sta. Maria
Imbaro12.00 Lunch break with poster session
6
▼
Saturday, October 13, 2007
Session IIICellular responses to chronic liver injuryChair: D. Lebrec, Clichy; M. Pinzani, Florence
13.00– Role of hepatic progenitor cells in regeneration T. Roskams,13.15 Leuven
13.20– The hepatic stellate cell: A progenitor cell C. Kordes,13.35 Düsseldorf
13.40– Role of nonparenchymal liver cells in portal hypertension V. Shah, 13.55 Rochester
14.00– Role of angiogenesis in portal hypertension M. Fernández,14.15 Barcelona
14.20– The relative roles of lymphocytes, Kupffer cells, and D. A. Brenner,14.35 myofibroblasts in hepatic fibrosis La Jolla
14.40– Hepatic fibrogenesis and carcinogenesis: S. L. Friedman,14.55 Krüppel-like factors and beyond New York
15.00 Coffee break with poster session
Session IVClinical management of progressive liver fibrosisChair: G. Ramadori, Göttingen; C. Trautwein, Aachen
15.20– Non-invasive assessment of liver fibrosis (1): D. Thabut,15.30 Serum surrogate markers Paris
15.30– Non-invasive assessment of liver fibrosis (2): M. Beaugrand,15.40 Fibroscan Paris
15.50– The clinical evaluation of disease progression in CLD: M. Pinzani,16.05 Towards an integrated systems? Florence
16.10– Fibrosis regression and innovative antifibrotic therapies: H. Wasmuth,16.25 From bench to bedside? Aachen
7
▼
Saturday, October 13, 2007
Session VClinical management of portal hypertension (1):Preprimary and primary prophylaxisChair: J. Heller, Bonn; F. Wong, Toronto
16.30– Dynamic increase of intrahepatic vascular resistance J.-C. Garcia-Pagán,16.45 in cirrhosis Barcelona
16.50– Remodelling portal hypertension: G. Garcia-Tsao,17.05 Preprimary prophylaxis New Haven
17.10– When and how to scope in portal hypertension R. de Franchis,17.25 Milan
17.30– Prevention of first variceal bleeding P. Calès,17.45 Angers
17.50 End of afternoon session
8
▼
Sunday, October 14, 2007
Session VIClinical management of portal hypertension (2):Complications of cirrhosisChair: J. Bosch, Barcelona; R. Wiest, Regensburg
8.15– Management of acute variceal bleeding A. K. Burroughs, 8.30 London
8.35– Prevention of variceal rebleeding D. Lebrec,8.50 Clichy
8.55– From sodium retention to therapy for refractory ascites: F. Wong,9.10 The role for new drugs? Toronto
9.15– The role of TIPS in the treatment of refractory ascites M. Rössle,9.30 Freiburg
9.35– Spontaneous bacterial peritonitis: A disease of the gut? – A. Cardenas,9.50 Therapeutic implications Barcelona
9.55 Coffee break with poster session
9
▼
10.20 Presentation of Poster Prizes A. K. Burroughs, London
10.30– Hepatorenal syndrome in cirrhosis A. Gerbes,10.45 Munich
10.50– Infections and hepatic encephalopathy D. Häussinger, 11.05 Düsseldorf
11.10– Liver and lung – Treatment of hepatopulmonary diseases P. Schenk,11.25 Vienna
11.30– Allocation in liver transplantation: Is MELD the solution? D. M. Heuman,11.40 North American perspective Richmond
11.40– Allocation in liver transplantation: Is MELD the solution? A. O. Rahmel,11.50 European perspective Leiden
12.00 Emerging future therapies for portal hypertension J. Bosch,12.25 Barcelona
12.30 Concluding remarks A. K. Burroughs, London
12.40 Farewell lunch
10
▼ Sunday, October 14, 2007
11
Poster SessionPosters will be exhibited on October 13-14, 2007, at the “International CongressCenter Dresden“.
The authors will be in attendance during coffee and lunch breaks on both days.
1. Hepatic cirrhosis in the elderly in a Hispano-American populationE. Aravena, F. Contesse, R. Muñoz, H. Iturriaga (Santiago de Chile, RCH)
2. Liver affection in different types of glycogen storage disease in childrenE.S. Dublina, E. Uvarova, T.V. Strokova, A.S. Potapov (Moscow, R)
3. Wilson disease in childhood: Results of a single center experienceM. Georgieva-Shakola, D. Konstantinova-Kanazireva, I. Krasnaliev, A. Atanassova, S. Tomova, A. Savov, V. Tzaneva (Varna, Sofia, BG)
4. Liver cirrhosis in cystic fibrosisK. Kalinova, K. Todorova (Stara Zagora, BG)
5. Niemann-Pick disease-type BD. Konstantinova-Kanazireva, M. Georgieva, V. Sinigerska, V. Tzaneva, L. Angelova (Varna, Sofia, BG)
6. Clinical features of pediatric liver cirrhosis resulting from alpha1-antitrypsindeficiencyI. Lastauka, M. Halabarodzka (Minsk, WR)
7. US scanning data in liver cirrhosis in infants of first 3 years oldT. Raeuneva, M. Halabarodzka (Minsk, WR)
8. H63D heterozygotes with alcoholic liver disease are proned to hypercholesterolemia: A single centre, prospective studyJ. Raszeja-Wyszomirska, I. Zawada, J. Suchy, G. Kurzawski, J. Lubinski, P. Milkiewicz (Szczecin, PL)
9. Natural history of primary sclerosing cholangitis in patients with inflammatorybowel disease: Our experienceP. Svorcan, D. Bojic, M. Protic, B. Bojic, S. Djorovic, J. Djordjevic, N. Jojic, S. Kazic, B. Dapcevic (Belgrade, SRB)
10. Copper and ceruloplasmin in sera of patients with alcoholic liver cirrhosisE. Uhlikova, V. Kupcová, M. Szántová, I. Vozár, L. Turecky (Bratislava, SK)
11. Hepatic stellate cells and liver regeneration in chronic viral hepatitis CS. Abdulhakov, N.A. Cheremina, A.A. Gumerova, M.A. Titova, A.P. Kiassov, L.Fatkheeva, T. Smetannikova, D.I. Andreeva (Kazan, R)
12. TGF-β and ethanol: Two substances that exponentiate each other leading toincreased liver damageK. Breitkopf, H. Gaitantzi, L. Ciuclan, P. Godoy, S. Dooley (Mannheim, D)
13. Cholestasis but not steatosis potentiates liver injury by activated Kupffer cells:Evidence for a role for cyclooxygenase 2M. Bystron, C.J. Steib, J.M. Härtl, F. Roggel, M. Bilzer, A.L. Gerbes (Munich, D)
14. Expression of C-kit in liver after partial hepatectomy in ratsI.M. Gazizov, M.S. Kaligin, D.I. Andreeva, G.O. Pevnev, G.R. Burganova, A.A.Gumerova, A.P. Kiassov (Kazan, R)
15. Perisinusoidal cells after partial hepatectomy in ratsI.M. Gazizov, M.S. Kaligin, D.I. Andreeva, G.O. Pevnev, G.R. Burganova, A.A.Gumerova, A.P. Kiassov (Kazan, R)
16. Hepatic overexpression of RhoA- and Rho-kinase and elevated Rho-kinaseactivity in livers from rats with CCI4-induced micronodular cirrhosisM. Hennenberg, J. Trebicka, A. Eckhardt, T. Sauerbruch, J. Heller (Bonn, D)
17. The association of intestinal iNOS expression and oxidative stress in the intes-tine in experimental cirrhosisM.R. Mas, B. Savas, R. Ocal, I. Tasci, A. Ensari, B. Comert, S. Yilmaz, A.T. Isik, N. Mas, E. Erden, Ö. Uzunalimoglu (Ankara, TR)
18. Large-conductance calcium-activated potassium channels modulate vascular tone in experimental cirrhosisA. Rodriguez-Vilarrupla, M. Graupera, V. Matei, R. Bataller-Sifre, J.G. Abraldes, J. Bosch, J.-C. Garcia-Pagán (Barcelona, Valencia, E)
19. Kupffer cell (KC) activation in fibrotic livers by β-glycans: The COX-2 inhibitorParecoxib reduces portal pressure (PP) incerase in vivoC.J. Steib, M. Bystron, J.M. Härtl, C. Opelz, I. Liss, B. Göke, A.L. Gerbes(Munich, D)
20. Stem cell properties of hepatic stellate cellsA.A. Gumerova, A.P. Kiassov, S. Abdulchakov, M.S. Kaligin, I.M. Gazizov, D.I.Andreeva (Kazan, R)
12
21. Effects of pentoxifylline on established liver fibrosis and hepatic stellate cellsafter bile duct ligation in ratM.R. Mas, R. Ocal, G. Bilgin, Y. Karslioglu, B. Comert, L. Ozsari, I. Tasci, N. Mas,A.T. Isik, Ö. Uzunalimoglu (Etlik, Ankara, TR)
22. CD95 ligand induces proliferation and CD95-tyrosine nitration in quiescent rathepatic stellate cellsR. Reinehr, A. Sommerfeld, S. Becker, D. Häussinger (Düsseldorf, D)
23. TGF-β signalling in hepatocytes promotes EMT and liver fibrogenesis, whereashepatocyte-specific expression of TGF-β antagonist Smad7 suffices to protectfrom liver damage and fibrogenesisH. Weng, L. Ciuclan, P. Godoy, S. Kanzler, R. Heuchel, E. Ueberham, R. Gebhardt, J. Hamzavi, P. Mertens, K. Breitkopf, S. Dooley (Mannheim,Mainz, Leipzig, D; Uppsala, S)
24. The role of ADH and ALDH gene polymorphism in alcohol liver cirrhosisH. Cichoz-Lach, K. Celinski, J. Partycka, M. Slomka (Lublin, PL)
25. Effect of copy number repeats of the CCL3L1 gene one susceptibility to HCVinfection and fibro-inflammatory responseF. Grünhage, O. Gressner, H. Keppeler, H. Wasmuth, M. Odenthal, U. Drebber, H.P. Dienes, C. Hellerbrand, T. Sauerbruch, F. Lammert (Bonn, Aachen, Cologne, Regensburg, D)
26. Genome wide scans for fibrosis susceptibility genes in experimental crosses ofinbred mouse strainsR. Hall, S. Hillebrandt, K. Hochrath, F. Grünhage, T. Sauerbruch, F. Lammert (Bonn, D)
27. Immunogenetic factors in the development of HCV-related liver cirrhosisA.O. Romanov, T.V. Belyaeva, E.V. Esaulenko (St. Petersburg, R)
28. Hypersecretory haplotype of interleukin-1 gene cluster increases the risk ofalcoholic liver cirrhosisJ. Sperl, J. Petrasek, S. Reznakova, J.A. Hubacek, F. Stickel, P. Trunecka, T. Berg,J. Spicák, M. Jirsa (Prag, CZ; Bern, CH; Berlin, D)
29. Beta-glucosidase 2 (GBA2) deficiency leads to zonal glucosylceramide accumu-lation in the liverY. Yildiz, H. Matern, S. Weber, S. Matern, D.W. Russell, T. Sauerbruch, F. Lammert (Bonn, Aachen, D; Dallas, USA)
13
30. Impact of peginterferon α-2b and ribavirin combined therapy on serum gastrin and progastrin concentrations in Helicobacter pylori (HP) infectedpatients with chronic hepatitis C (CHC)W. Bielanski, W.W. Mazur, Z. Gonciarz, M. Gonciarz, S.J. Konturek, M. Magiera, J.F. Rehfeld (Cracow, Chorzów, Sosnowiec, PL; Copenhagen, DK)
31. Researches on the immunologic-inflammatory answer at the patients chronically infected with the hepatitis virus CM. Deac, M. Boitan, R. Mihaila, A. Fraticiu, C.E. Rezi, A.V. Zaharie, A. Olteanu, D. Dascalu, L. Tiurean, P.-J. Porr, C.C. Cipaian, D.V. Vulcu, O. Petrascu, C.B. Beca, A.B. Boicean, L. Chicea, D. Orga-Dumitriu, C. Bidlo, A. Catana, R. Mihaila (Sibiu, RO)
32. Detection of SEN virus in chronic hepatitis C virus infected patients genotype 4 and sequencing in EgyptS.A. Girgis, A. Monis (Cairo, ET)
33. Clearance of HCV improves insulin resistance and early insulin secretion ofpancreas in chronic hepatitis C patientsR. Narita, M. Hiura, S. Abe, A. Tabaru, M. Otsuki (Kitakyushu, J)
34. Relationship of serum interleukin-6 and alpha tumor necrosis factor levels withthe metabolic syndrome in NASH patientsC.E. Rezi, M. Boitan, R. Mihaila, A. Fraticiu, A.V. Zaharie, A. Olteanu, D. Dascalu, L. Tiurean, M. Deac, P.-J. Porr, C.C. Cipaian, D.V. Vulcu, O.Petrascu, C.B. Beca, A.B. Boicean, L. Chicea, D. Orga-Dumitriu, C. Bidlo, V. Crangaciu, A. Catana, R. Mihaila (Sibiu, RO)
35. Correlation between development of liver fibrosis and intrahepatic bile ducts'state in chronic viral hepatitis and PBCL. Fatkheeva, A. A. Goumerova, A.P. Kiassov, A.S. Sozinov, M. Fatkheeva(Kazan, R)
36. Serum fibronectin as marker of liver regenerative processL.S. Gotia, S.R. Gotia, D. Verdes, L.M. Susan (Timisoara, RO)
37. Is serum hyaluronic acid a marker of liver fibrosis in acute and chronic liver dis-ease?J. Keiss, V. Sondore, N. Sevastjanova, B. Rozentale, L. Viksna (Riga, LV)
38. APRI in chronic hepatitis C patients with AST levels equal or below 1.5 ofupper limit of normal. To do or not to do?O. Kosseva, E. Pophristova, K. Antonov, D.G. Adjarov, Z. Krastev (Sofia, BG)
14
39. Comparison of three non-invasive methods for the diagnosis of liver fibrosis inchronic hepatitis BO. Kosseva, E. Pophristova, E. Kaneti, S. Bocheva, D.G. Adjarov, Z. Krastev (Sofia, BG)
40. Assessment of cholestasis and fibrogenesis in patients with primary biliary cir-rhosisV. Kupcová, L. Turecky, M. Valková, M. Szántová, E. Uhlíková, S.Z. Zigraiová (Bratislava, SK)
41. Serum gammaglutamyltranspeptidase, steatosis and fibrosis in chronic virus ChepatitisB. Mihai, C. Mihai, C. Cijevschi, C. Lacatusu, P. Gogalniceanu (Iasi, RO; Lon-don, GB)
42. Alpha-2-macroglobulin in sera of patients with chronic hepatopathies andeffect of liver transplantation on level of this markerL. Turecky, V. Kupcová, M. Szántová, E. Uhliková (Bratislava, SK)
43. Is IGF-1 response to growth hormone administration in cirrhosis reflect morehepatocellular dysfunction rather than portal hypertension and malnutrition?N. Assy, Y. Pruzansky, Z. Hochberg, D. Gaitini, Z. Shen Orr, Y. Baruch (Safed,Haifa, IL)
44. Investigation of isoenzymes of gamma-glutamyltransferase and bile acids inchronic liver diseasesV. Kupcová, L. Turecky, E. Uhliková, M. Szántová, A. Krsáková (Bratislava, SK)
45. Investigation of serum cytokines in chronic viral hepatitis after IFN-αtreatmentV. Kupcová, L. Turecky, Z. Zelinkova, M. Valková, E. Seligová (Bratislava, SK)
46. Study of the relationship between chronic hepatitis C infection, non-alcoholicfatty liver disease (NAFLD) and insulin resistanceN.M. Mashaal, A.A. Abdel Moety, E.A. Shaat, R.A.O El Sheikh (Alexandria, ET)
47. The study of correlation between IL-6 and TNF alpha and the biochemical livertests at the patients chronically infected with the hepatitis virus CR. Mihaila, M. Boitan, A. Fraticiu, C.E. Rezi, A.V. Zaharie, A. Olteanu, D. Dascalu, L. Tiurean, M. Deac, P.-J. Porr, C.C. Cipaian, D.V. Vulcu, O. Petrascu, C.B. Beca, A.B. Boicean, L. Chicea, D. Orga-Dumitriu, C. Bidlo, A. Catana, R. Mihaila (Sibiu, RO)
15
48. The study of correlation between IL-6, TNF alpha and erythropoietin with thebiochemical liver tests at the patients with non-alcoholic fatty liver diseaseR. Mihaila, M. Boitan, R. Mihaila, C.E. Rezi, A. Fraticiu, A.V. Zaharie, A. Olteanu, D. Dascalu, L. Tiurean, M. Deac, P.-J. Porr, C.C. Cipaian, D.V. Vulcu, O. Petrascu, C.B. Beca, A.B. Boicean, L. Chicea, D. Orga-Dumitriu, C. Bidlo, A. Catana (Sibiu, RO)
49. Serum apoptotic cytokeratin 18 neoepitope in acute and chronic liver damageV. Sondore, J. Keiss, N. Sevastjanova, L. Viksna, B. Rozentale (Riga, LV)
50. Study of the correlation between nitric oxide profile, degree of liver injury andstructural vascular changes of the gastric mucosa in chronic hepatitis C virusrelated liver diseasesM.Y. Taher, H. El Saed, N.M. Baddour, A.A. Abdel Moety, A. Zeid (Alexandria, ET)
51. Serum selenium and carnitine concentrations of cirrhotic childrenN. Uslu, I.N. Saltik-Temizel, H. Demir, F. Gürakan, H. Özen, A. Yüce (Ankara,TR)
52. On the optimization of the 13C-alpha-ketoisocaproic acid breath test – An in-depth study speaks for an extended breath sampling periodK. Jonderko, A. Kasicka-Jonderko, M. Kaminska, M. Bielecka, B. Blonska-Fajfrowska (Sosnowiec, PL)
53. Band ligation vs. miniloops in the endoscopic treatment of esophageal varices -Comparative pilot studyC. Banciu, L.M. Susan, O. Chirileanu, L. Marian, I. Romosan (Timisoara, RO)
54. Upper digestive bleeding in liver cirrhosisC. Cijevschi, C. Mihai, V. Drug, P. Gogalniceanu (Iasi, RO; London, GB)
55. Upper digestive haemorrhage in cirrhosis - Prevalence and precipitating factorsD. Damian, M. Grigorescu, A. Berecz, M. Hogea, M. Rusu (Cluj-Napoca, RO)
56. Upper gastrointestinal bleeding in cirrhosis - Clinical aspects and evolutionD. Damian, M. Grigorescu, A. Berecz, M. Hogea, M. Rusu (Cluj-Napoca, RO)
57. Major complications in liver cirrhosisC. Mihai, C. Cijevschi, B. Mihai, V. Drug, P. Gogalniceanu (Iasi, RO;London, GB)
16
58. Use of clonidine in cirrhotic patients with large diuretic resistant ascitis –Prospective pilot studyC. Banciu, L.M. Susan, V. Vacariu, C. Dascau, L. Marian, I. Romosan (Timisoara,RO)
59. Superiority of the serum-ascites albumin gradient over the ascites total protein concentration in diseases with ascitesN. Colic, D. Vrinic, A. Colic, S. Kazic, P. Svorcan, D. Necic, B. Dapcevic (Bel-grade, SRB)
60. The evolution of spontaneous bacterial peritonitis under medical treatment incirrhotic patients with ascitesA. Genunche-Dumitrescu, P. Mitrut, D. Badea, M. Badea (Craiova, RO)
61. E. coli lipopolysaccharides antibodies (CLA) and some species of chronic hepa-titis and liver cirrhosisB.N. Levitan, A. Umerova, G. Levitan (Astrakhan, R)
62. Bacterial translocation in cirrhotic rats: Therapeutic role if iNOS inhibitor S-methylisothioureaM.R. Mas, S. Yilmaz, Ö. Uzunalimoglu, M. Ozyurt, I. Tasci, A.T. Isik, A. Ozcan, B. Comert, N. Mas, C. Akay, H. Bozkaya, C. Yurdaydin (Ankara,Istanbul, TR)
63. Enzymes of purine degradation in lymphocytes of patients with liver cirrhosisL. Turecky, V. Kupcová, V. Rendekova, M. Szántová, E. Uhliková (Bratislava, SK)
64. Hepatorenal syndrome is a major complication of end stage liver cirrhosis andhas a poor prognosisB. Appenrodt, J. Zielinski, J. Heller, T. Sauerbruch, M. Schepke (Bonn, D)
65. Assessment of the renal hemodynamics in liver cirrhosis with duplex-DopplerultrasonographyA. Caraba, L.M. Susan, A. Pacurari, I. Romosan (Timisoara, RO)
66. Predictive diagnosis of hepatorenal syndromeP. Mitrut, A. Genunche-Dumitrescu (Craiova, RO)
67. Predictor factors in development of hepatopulmonary syndrome in patientswith liver cirrhosisA. Genunche-Dumitrescu, P. Mitrut, D. Badea, M. Badea (Craiova, RO)
17
68. Pulmonary hypertension, a rare but dreaded complication of liver cirrhosisM. Marin, O. Chira, S. Tanu, V. Mercea (Cluj-Napoca, RO)
69. Impaired cardiovagal autonomic function in patients with chronic hepatitis C: Isthere an association with sensory nerve function and cryoglobulinaemia?J. Osztovits, T. Horvath, Z. Visnyei, T. Csák, G. Bekö, P.L. Lakatos, G. Lengyel, E.Ibranyi, T. Toth, M. Abonyi, J. Feher, P. Kempler, M. Kollai, F. Szalay (Budapest, H)
70. The etiological spectrum of portal hypertension in pediatric population – Evolu-tion and treatment (5 years retrospective study)A. Constantinescu, C. Gheorghe, L. Gheorghe, C. Nicolae, I. Lupescu, V. Herlea, A. Constantinescu, I. Popescu, C. Arion (Bucharest, RO)
71. Prehepatic portal hypertension in patients with portal thrombosis: Clinical andlaboratory characteristicsE. Kitsenko, E. Lukina, E.P. Sysojeva, E. Voronkova, E. Lubivy, G. Sukhanova, S. Vasiljev (Moscow, R)
72. Myeloproliferative disorders in patients with prehepatic portal hypertensionE.P. Sysojeva, E. Lukina, E. Semenova, E. Voronkova, N. Khoroshko, G.A. Frank (Moscow, R)
73. Minimal hepatic encephalopathy: The role of neuropsychological assessment in the diagnosisG. Jankovic, Z. Djuric, D. Mijac, E. Stefanova (Belgrade, SRB)
74. Efficacy of flumazenil administered in small repeated intravenous doses inpatients with hepatic encephalopathyJ.J. Jovic, N.J. Jovic, T. Pecelj-Brocic, B. Roganovic (Belgrade, SRB)
75. Prognostic significance of bacterial infection as precipating factors of chronic hepatic encephalopathy in cirrhosisS. Naumovski-Mihalic, M. Katicic, V. Colic-Cvrlje, B. Papa, T. Filipec-Kanizaj, M. Ticak, B. Sabaric, B. Skurla (Zagreb, HR)
76. The role of Helicobacter pylori infection for development of portal encephalopathyD. Neagoe, G. Ianosi, A. Saftoiu, C. Vere, F. Racanel, D. Tudorascu (Craiova, RO)
77. Hepatic encephalopathy does not correlate with depression and quality of lifein patients with liver cirrhosis: A single centre, prospective studyE. Wunsch, I. Zawada, M. Kaczmarczyk, E. Gebala, P. Milkiewicz (Szczecin, PL)
18
78. UDCA in the treatment of primary biliary cirrhosisK. Kalinova (Stara Zagora, BG)
79. The somatostatin analogue octreotide inhibits angiogenesis and VEGF expres-sion in the early, but not in advanced, stages of portal hypertension in rats.Role of somatostatin receptor subtype 2 downregulation during the evolutionof the portal hypertensive syndromeM. Mejias, E. Garcia-Pras, J. Bosch, M. Fernandez (Barcelona, E)
80. Comparison of two statins efficacy on a reversibility of experimental rat liverfibrosisO. Lukivskaja, Y. Popov, J. Zaks, D. Schuppan, V.U. Buko (Grodno, WR; Boston,USA)
81. Effect's evaluation of the treatment with carvedilol versus propranolol andisosorbide-5-mononitrate on hepatic haemodynamic parameters in patientswith liver cirrhosisE. Tcaciuc, S. Matcovschi, A. Tcaciuc, N. Nacu (Chisinau, MOL)
82. The efficacy of the treatment with Losartan and Ursofalk versus only Losartanon hepatic haemodynamic parameters in patients with compensated liver cirrhosisA. Tcaciuc, S. Matcovschi, E. Tcaciuc, N. Nacu (Chisinau, MOL)
83. Atorvastatin inhibits fibrogenesis by inhibiting Ras and RhoA activationJ. Trebicka, M. Neef, K. Shir, M. Hennenberg, F. Lammert, J. Reichen, T. Sauerbruch, J. Heller (Bonn, D; Bern, CH)
84. Urotensin II receptor antagonist palosuran lowers portal pressure by activationof mesenterial RhoA/Rho-kinase signalling in liver cirrhosisJ. Trebicka, A. Eckhardt, M. Hennenberg, E. Biecker, F. Lammert, T. Sauerbruch,J. Heller (Bonn, D)
85. Antioxidant taurine treatment in experimental liver fibrosisÖ. Uzunalimoglu, M.R. Mas, S.A. Vural, S. Deveci, C. Akay, A.T. Isik, M. Bozdayi (Ankara, Etlik, TR)
86. Nutritional state in alcoholic liver cirrhosisJ. Daniluk, E. Krzyzanowska, A. Zwolak (Lublin, PL)
87. Affective alterations: Determinant factor of sleep disorders in cirrhotic patientsM. González, J. Poniachick, M. Cumsille, A.M. Madrid, J. Brahm (Santiago deChile, RCH)
19
88. Impaired health-related quality of life in Romanian patients with hepatic cirrhosisC. Pojoga, D.L. Dumitrascu (Cluj-Napoca, RO)
89. Fatigue, depression and functional disability in patients with liver cirrhosisG. Stefanescu, C. Stefanescu (Iasi, RO)
90. Total paracentesis with albumin infusion in patients with ascites before radiofrequency ablation (RFA) of hepatocellular carcinoma (HCC)J. Genov, N. Grigorov, R. Mitova, B. Golemanov (Sofia, BG)
91. S-100 and GFAP-positive cells in human liver cirrhosis and in human hepatocellular cancerM.V. Gulubova, T. Vlaykova, V. Velev (Stara Zagora, BG)
92. Frequency of hepatocellular carcinoma in chronic viral infectionsD. Svarc (Novi Sad, SRB)
93. Expression of the reactive oxygen species-detoxifying enzymes, GST-PI andCU/ZN-SOD in cirrhosis and hepatocellular carcinomaT. Vlaykova, M.V. Gulubova (Stara Zagora, BG)
94. Orthotopic liver transplantation for chronic hepatitis BS. Frankova, P. Trunecka, J. Sperl, M. Adamec, J. Spicák, S. Vitko (Prague, CZ)
95. Plasma value of endothelin-1 versus renal and liver function in patients afterorthotopic liver transplantation in long-term follow upH. Gottfriedova, O. Schück, L. Karasová, M. Stollová, J. Maly, J. Skibová,P. Trunecka, J. Spicák (Prague, CZ)
96. Absence of teratogenicity of sirolimus used during early pregnancy in a livertransplant recipientI. Jankowska, U. Oldakowska-Jedynak, Z. Jabiry-Zieniewicz, A Cyganek,J. Pawlowska, M. Teisseyre, P. Kalicinski, L. Paczek, J. Socha (Warsaw, PL)
97. Recurrence of nonalcoholic steatohepatitis in transplanted liver in a 13-year-oldboyI. Jankowska, P. Socha, J. Pawlowska, M. Teisseyre, D. Gliwicz, P. Kalicinski, J. Cielecka-Kuszyk, J. Socha (Warsaw, PL)
98. Activation of latent TGF-β inside the hepatocyte leads to target gene expression via autocrine, intracellular signalling – Relevance for the initiation ofacute and chronic liver injuryO.A. Gressner, B. Lahme, M. Siluschek, K. Rehbein, R. Weiskirchen, A.M. Gressner (Aachen, D)
20
21
List of Speakers, Moderators and Scientific Organizers
Prof. Dr. David H. AdamsQueen Elizabeth HospitalInstitute of Clinical SciencesLiver Research LaboratoriesBirmingham B15 2THGreat [email protected]
Prof. Dr. Michel BeaugrandHôpital Jean VerdierService d'Hepato-Gastro-Ent.Ave. du 14-Juillet93140 [email protected]
Prof. Dr. Jaime BoschHospital Clinico y ProvincialUniversidad de BarcelonaVillarroel 17008036 [email protected]
David A. Brenner, M.D.Professor of MedicineUniv. of Columbia, San DiegoSchool of MedicineHealth Sciences9500 Gilman DriveLa Jolla CA [email protected]
Prof. Dr. Andrew. K. BurroughsRoyal Free HospitalSchool of MedicineDepartment of MedicinePond StreetLondon NW3 2QGGreat [email protected]
Prof. Dr. Paul CalèsCentre HospitalierDépartement de Hépatologie49033 [email protected]
Dr. A. CardenasHospital Clinico y ProvincialUniversidad de BarcelonaUnidad de HepatologiaVillarroel 17008036 [email protected]
Dr. Mercedes FernandezHospital Clinico y ProvincialUniversidad de BarcelonaHepatic Hemodynamic LaboratoryLiver UnitVillarroel 17008036 [email protected]
Prof. Dr. Roberto de FranchisUniversità di MilanoIRCCS Ospedale Maggiore Pol.Dipartimento di Medicina InternaServizio di GastroenterologiaVia Pace, 920122 [email protected]
Scott L. Friedman, M.D.Professor of MedicineMount Sinai School of MedicineRoom 11-70F1425 Madison Ave.New York NY [email protected]
22
Dr. Juan Carlos Garcia-PagánHospital Clinico y ProvincialUniversidad de BarcelonaHepatic Hemodynamic LaboratoryVillarroel 17008036 [email protected]
Guadalupe Garcia-Tsao, M.D.Professor of MedicineYale UniversitySchool of MedicineSection of Digestive Diseases333 Cedar StreetNew Haven CT [email protected]
Prof. Dr. Alexander L. GerbesInnere Medizin IIKlinikum der UniversitätMünchen - GroßhadernMarchioninistr. 1581377 Mü[email protected]
Prof. Dr. Axel M. GressnerKlinische Chemie/ZentrallaborUniversitätsklinikum AachenPauwelsstr. 3052074 [email protected]
Prof. Dr. Dieter HäussingerGastroenterologie/HepatologieUniversitätsklinikum DüsseldorfMoorenstr. 540225 Dü[email protected]
PD Dr. Jörg HellerMedizinische Klinik IUniversitätsklinikum BonnSigmund-Freud-Str. 2553127 [email protected]
PD Dr. Claus HellerbrandKlinik und Poliklinik für Innere Medizin IKlinikum der Universität Regensburg93042 [email protected]
Douglas M. Heuman, M.D.Professor of MedicineVirginia Commonwealth UniversityMcGuire VA Medical CenterHepatology & Liver TransplantationP.O. Box 980341Richmond VA [email protected]
Hartmut W. Jaeschke, Ph.D.Professor of ToxicologyUniversity of KansasMedical CenterDepartment of Pharmacology,Toxicology & Therapeutics, MS 10183901 Rainbow Blvd.Kansas City KS [email protected]
Dr. Claus KordesGastroenterologie/HepatologieUniversitätsklinikum DüsseldorfMoorenstr. 540225 Dü[email protected]
23
Prof. Dr. Frank LammertMedizinische Klinik IUniversitätsklinikum BonnSigmund-Freud-Str. 2553127 [email protected]
Prof. Dr. Didier LebrecHôpital BeaujonInserm U 481100, Bd. Général Leclerc92118 [email protected]
Dr. Antonio MoschettaUniversitá di BariConsorzio Mario Negri SudCentro Ricerche Farmacologichee BiomedicheVia Nazionale 8/A66030 Sta. Maria Imbaro (Chieti)[email protected]
Prof. Dr. Massimo PinzaniUniversità di FirenzeOspedale CareggiFisiopatologia EpaticaClinica Medica IIViale G.B. Morgagni 8550134 [email protected]
Dr. Axel O. RahmelEurotransplantInternational FoundationP.O. Box 23042301 CH [email protected]
Prof. Dr.Dr.h.c. Giuliano RamadoriGastroenterologieUniversitätskliniken GöttingenRobert-Koch-Str. 4037075 Gö[email protected]
Prof. Dr. Tania RoskamsCatholic University of LeuvenUniversity Hospital St. RafaelDepartment of PathologyMinderbroederstraat 123000 [email protected]
Prof. Dr. Martin RössleInternistBertoldstr. 4879098 [email protected]
Prof. Dr. Tilman SauerbruchMedizinische Klinik IUniversitätsklinikum BonnSigmund-Freud-Str. 2553127 [email protected]
Dr. Peter SchenkMedizinische Universität WienInnere Medizin IV, 13H3Währinger Gürtel 18-201090 [email protected]
Vijay Shah, M.D.Assistant Professor of MedicineMayo ClinicGI Research UnitAlfred 2-435200 First Street SWRochester MN [email protected]
Prof. Dr. Ulrich SpenglerMedizinische Klinik IUniversitätsklinikum BonnSigmund-Freud-Str. 2553127 [email protected]
Dr. Dominique ThabutHôpital Pitié SalpêtrièreHepato-GastroenterologyAP-HP Groupe47–83, boulevard de l’Hopital75013 [email protected]
Prof. Dr. Christian TrautweinMedizinische Klinik IIIUniversitätsklinikum AachenPauwelsstr. 3052074 [email protected]
PD Dr. Hermann WasmuthMedizinische Klinik IIIUniversitätsklinikum AachenPauwelsstr. 3052074 [email protected]
PD Dr. Ralf WeiskirchenKlinische Chemie/PathobiochemieUniversitätsklinikum AachenPauwelsstr. 3052074 [email protected]
PD Dr. Reiner WiestKlinik für Innere Medizin IKlinikum derUniversität Regensburg93042 [email protected]
24
Prof. Dr. Florence WongUniversity of TorontoToronto General Hospital9EN/220200 Elizabeth StreetToronto ON M5G [email protected]
25
Congress OfficeDuring the II Falk Gastro-Conference
International Congress Center Dresden Telephone: +49(0)351/2 16-15 15Ostra-Ufer 2 Telefax: +49(0)351/2 16-17 1501067 DresdenGermany
Opening Hours:Tuesdayday, October 9, 2007 16.00–21.00 hWednesday, October 10, 2007 18.30–21.00 hThursday, October 11, 2007 18.00–17.30 hFriday, October 12, 2007 18.00–19.30 hSaturday, October 13, 2007 18.15–17.40 hSunday, October 14, 2007 17.45–13.00 h
Parking:Parking at the “International Congress Center Dresden” is free of charge for partici-pants of the congress. However, before leaving, the regular parking ticket must beexchanged for a “free parking ticket” at the Congress Office.
Congress FeesScientific program of the Falk Symposium 162 € 150,-Students and residents € 175,-
***OR***
Day ticket, Saturday, October 13, 2007 € 120,-Students and residents € 60,-
Admission ticket for Sunday morning, October 14, 2007 € 60,-Students and residents € 30,-
The congress fees include:– Refreshments during coffee breaks– Lunch on October 13 and 14, 2007– A copy of the symposium’s abstract volume– Parking at the “International Congress Center Dresden“
Admission to Scientific EventsFor admission to scientific events your name badge should be clearly visible.
26
Congress ReportThe official congress report of the Falk Symposium 162 “Future Perspectives in Gastroenterology” will be published in English in the first half of 2008 by Springer,Dordrecht, Netherlands. Orders for this book at a reduced subscription price of € 30,- can be placed at the Congress Office during the congress in Dresden.
Congress Short ReportThe congress short report of the II Falk Gastro-Conference will be published by theFalk Foundation e.V. with number FSK 161-162 in the first half of 2008.
Orders for this short report, free of charge, can be placed with the Falk Foundation e.V.
AirportInternational Airport Dresden
General Information:
Falk Foundation e.V.Congress DivisionLeinenweberstraße 5P.O. Box 652979041 Freiburg/Br.GermanyTelephone: +49(0)761/15 14-0Telefax: +49(0)761/15 14-359E-Mail: [email protected]
www.falkfoundation.de
P 16
2e 1
-9/2
007/
600
Stü
![Peer Learning Event on Assessment and Demonstration of ... with Case Studies... · Universities of Applied Sciences [Vereniging Hogescholen] 10.50-11.10 3.B Andy Gibbs BSC (Hons),](https://static.documents.pub/doc/80x56/5c73f3c409d3f28e198bde6e/peer-learning-event-on-assessment-and-demonstration-of-with-case-studies.jpg)
